 Connection
Susan Calcaterra to Buprenorphine
This is a "connection" page, showing publications Susan Calcaterra has written about Buprenorphine.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
5.745 |
|
|
|
-
Calcaterra SL, Lockhart S, Natvig C, Mikulich S. Barriers to initiate buprenorphine and methadone for opioid use disorder treatment with postdischarge treatment linkage. J Hosp Med. 2023 10; 18(10):896-907.
Score: 0.698
-
Calcaterra SL, Martin M, Englander H. Identifying Barriers to OUD Treatment Linkage From the Emergency Department to the Community. JAMA Netw Open. 2023 05 01; 6(5):e2312683.
Score: 0.683
-
Calcaterra SL, Bottner R, Martin M, Englander H, Weinstein ZM, Weimer MB, Lambert E, Ronan MV, Huerta S, Zaman T, Ullal M, Peterkin AF, Torres-Lockhart K, Buresh M, O'Brien MT, Snyder H, Herzig SJ. Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines. J Hosp Med. 2022 09; 17(9):679-692.
Score: 0.648
-
Calcaterra SL, Lockhart S, Callister C, Hoover K, Binswanger IA. Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers. J Gen Intern Med. 2022 08; 37(11):2786-2794.
Score: 0.623
-
Callister C, Lockhart S, Holtrop JS, Hoover K, Calcaterra SL. Experiences with an addiction consultation service on care provided to hospitalized patients with opioid use disorder: a qualitative study of hospitalists, nurses, pharmacists, and social workers. Subst Abus. 2022; 43(1):615-622.
Score: 0.614
-
Calcaterra SL, Binswanger IA, Edelman EJ, McNair BK, Wakeman SE, O'Connor PG. The impact of access to addiction specialist on attitudes, beliefs and hospital-based opioid use disorder related care: A survey of hospitalist physicians. Subst Abus. 2022; 43(1):143-151.
Score: 0.553
-
Calcaterra SL, Klie KA. Methadone, Buprenorphine, or Detoxification for Management of Perinatal Opioid Use Disorder: A Cost-Effectiveness Analysis. Obstet Gynecol. 2020 04; 135(4):975.
Score: 0.552
-
Terasaki D, Smith C, Calcaterra SL. Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol. Pharmacotherapy. 2019 10; 39(10):1023-1029.
Score: 0.528
-
Callister C, Porter S, Vatterott P, Keniston A, McBeth L, Mann S, Calcaterra SL, Limes J. The Impact of Completing X-Waiver Training and Clinical Addiction Exposure on Internal Medicine Residents Treating Patients With Opioid Use Disorder. Subst Use Addctn J. 2024 Jul; 45(3):356-366.
Score: 0.179
-
Stern SJ, D'Orazio JL, Work BD, Calcaterra SL, Thakrar AP. Point/counterpoint: Should full agonist opioid medications be offered to hospitalized patients for management of opioid withdrawal? J Hosp Med. 2024 Apr; 19(4):339-343.
Score: 0.178
-
Terasaki D, Kulick B, Calcaterra S, Ray L. Phenobarbital for alcohol withdrawal in the context of the opioid epidemic: a neglected caveat. Addiction. 2023 07; 118(7):1198-1200.
Score: 0.170
-
Jawa R, Tin Y, Nall S, Calcaterra SL, Savinkina A, Marks LR, Kimmel SD, Linas BP, Barocas JA. Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics. JAMA Netw Open. 2023 04 03; 6(4):e237888.
Score: 0.170
-
Ritvo AD, Calcaterra SL, Ritvo JI. Using Extended Release Buprenorphine Injection to Discontinue Sublingual Buprenorphine: A Case Series. J Addict Med. 2021 May-Jun 01; 15(3):252-254.
Score: 0.149
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|